SGLT2 inhibitors: one bounded, context-dependent signal across receipts

Source literature boundary memo

Research question

Across retrieved fact-level receipts for SGLT2 inhibitors, which endpoints show directionally favorable versus null/non-convergent signals, and what matched PICO remains untested?

Selection criteria

The source-literature fallback selected SGLT2 inhibitors because the domain snapshot exposed enough fact-backed, topic-overlapping papers. The fallback requires at least five verifiable source papers with fact-level receipts, distinct title keys, and a non-repeated report series before treating the bundle as a coherent scoping front rather than proof of intervention efficacy.

Boundary map

• Sodium‐Glucose Cotransporter‐2 Inhibitors After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Population‐Based Investigation [primary; 2023] doi:10.1161/jaha.122.027824
  • Finding: the early use of SGLT2 inhibitors was associated with lower risks of the primary end point (HR 0.68 [95% CI, 0.54-0.87]; P=0.002)
  • Population: patients with type 2 diabetes and acute myocardial infarction undergoing percutaneous coronary intervention
  • Intervention/exposure: early use of SGLT2 inhibitors
  • Comparator: no use of SGLT2 inhibitors
• Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis [review; 2022] doi:10.1186/s12933-022-01455-2
  • Finding: Initiation of SGLT2 inhibitors in patients with AHF reduced the risk of rehospitalization for heart failure (OR 0.52; 95% CI [0.42, 0.65])
  • Population: patients hospitalized with acute heart failure
  • Intervention/exposure: SGLT2 inhibitors initiation
  • Comparator: placebo
• Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta‐Analysis of Randomized‐Controlled Trials [review; 2021] doi:10.1161/jaha.120.019463
  • Finding: those with heart failure treated with SGLT2 inhibitors had a 20% relative risk reduction in cardiovascular deaths and heart failure hospitalizations (risk ratio, 0.78; P<0.001).
  • Population: patients without diabetes mellitus with heart failure
  • Intervention/exposure: SGLT2 inhibitors
  • Comparator: not treated
• SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies [review; 2021] doi:10.1016/j.phrs.2021.105836
  • Finding: reduced risk of stroke with SGLT2 inhibitors compared to DPP-4 inhibitors (Hazard ratio HR, 0.89; 95%CI, 0.82-0.96)
  • Population: patients with type 2 diabetes mellitus
  • Intervention/exposure: SGLT2 inhibitors
  • Comparator: DPP-4 inhibitors
• Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis [review; 2021] doi:10.1093/eurjpc/zwab173
  • Finding: SGLT2i treatment significantly improved LV ejection fraction [SMD, 0.35; 95% CI (0.04, 0.65); P = 0.03]
  • Population: patients with type 2 diabetes mellitus and/or heart failure (13 RCTs, 1251 patients)
  • Intervention/exposure: sodium-glucose cotransporter-2 inhibitors (SGLT2i)
  • Comparator: control

Source synthesis

This receipt-backed scoping note has one bounded signal: SGLT2 inhibitors shows directionally consistent signals across heterogeneous contexts across this 5-source primary/review bundle (2021-2023). Grouped by direction: directionally favorable: 5 receipt(s). The source facts cover 5 population context(s) and 4 intervention/exposure context(s), so this is a scoping signal about where endpoints diverge, without establishing a causal, clinical, species-translated, or mechanistically integrated claim. Direction is homogeneous: all selected receipts are directionally favorable. The boundary is population, comparator, and endpoint diversity, not directional disagreement. The listed effect sizes remain source-specific across endpoints and populations; they are not pooled or averaged. This is a heterogeneous indication/context map, not a unified disease-specific or endpoint-family claim. Concrete source-level examples: the early use of SGLT2 inhibitors was associated with lower risks of the primary end point (HR 0.68 [95% CI, 0.54-0.87]; P=0.002); Initiation of SGLT2 inhibitors in patients with AHF reduced the risk of rehospitalization for heart failure (OR 0.52; 95% CI [0.42, 0.65]); those with heart failure treated with SGLT2 inhibitors had a 20% relative risk reduction in cardiovascular deaths and heart failure hospitalizations (risk ratio, 0.78....

Directional grouping

• directionally favorable: SGLT2 inhibitors is the intervention/exposure and the reported clinical endpoint favors that arm.

• comparator/not favorable: SGLT2 inhibitors is the comparator arm; the label is limited to that head-to-head endpoint.

• economic/context only: the receipt reports cost, QALY, or economic context rather than a clinical efficacy endpoint.

• non-clinical/predictive: the receipt reports descriptive modelling, prediction, or age-clock performance rather than an intervention endpoint.

• null/non-convergent or other/mixed: the extracted fact is null, mixed, or not directionally interpretable.

• directionally favorable: Sodium‐Glucose Cotransporter‐2 Inhibitors After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Population‐Based Investigation — the early use of SGLT2 inhibitors was associated with lower risks of the primary end point (HR 0.68 [95% CI, 0.54-0.87]; P=0.002)

• directionally favorable: Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis — Initiation of SGLT2 inhibitors in patients with AHF reduced the risk of rehospitalization for heart failure (OR 0.52; 95% CI [0.42, 0.65])

• directionally favorable: Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta‐Analysis of Randomized‐Controlled Trials — those with heart failure treated with SGLT2 inhibitors had a 20% relative risk reduction in cardiovascular deaths and heart failure hospitalizations (risk ratio, 0.78; P<0.001).

• directionally favorable: SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies — reduced risk of stroke with SGLT2 inhibitors compared to DPP-4 inhibitors (Hazard ratio HR, 0.89; 95%CI, 0.82-0.96)

• directionally favorable: Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis — SGLT2i treatment significantly improved LV ejection fraction [SMD, 0.35; 95% CI (0.04, 0.65); P = 0.03]

Specific moderators in this bundle are population/indication (patients hospitalized with acute heart failure; patients with type 2 diabetes and acute myocardial infarction undergoing percutaneous coronary intervention; patients with type 2 diabetes mellitus; patients with type 2 diabetes mellitus and/or heart failure (13 RCTs, 1251 patients); patients without diabetes mellitus with heart failure), study design/evidence type (primary/review). Single primary-study estimates are separated from pooled review or meta-analytic estimates rather than treated as interchangeable.

Context separation

The selected receipts group because each carries a fact-level extraction for SGLT2 inhibitors; they separate by context (human clinical/observational) and endpoint, so they are not interchangeable evidence for one pooled claim.

Boundary limits

Source-literature boundary for SGLT2 inhibitors: the listed sources define one bounded, context-dependent signal across separate source contexts. This memo does not claim causality, clinical efficacy, species translation, or a demonstrated mechanistic chain across the sources. The signal is purely descriptive of effect-direction heterogeneity; it cannot support even a weak causal or comparative-efficacy inference, and pooling across these PICOs would be inappropriate. Routing domain longevity_research is publication-lane metadata only; the source scope here is defined by the selected SGLT2 inhibitors receipts.

Next gaps

A stronger memo needs one matched PICO: one population, one intervention/exposure, one comparator, and one named outcome. If SGLT2 inhibitors is promoted beyond a scoping note, the next run should select sources sharing one context family rather than mixing human clinical/observational.